[CERU] Cerulean Pharma Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 57.18 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.75 Change: -0.02 (-2.08%)
Ext. hours: Change: 0 (0%)

chart CERU

Refresh chart

Description: Cerulean Pharma Inc., a clinical-stage company, develops nanopharmaceutical product candidates in the areas of oncology and other diseases in the United States. The company?s lead product candidate is CRLX101, a tumor targeted nanopharmaceutical, which is in Phase II clinical trials for the treatment of relapsed renal cell carcinoma and relapsed ovarian cancer; and in Phase Ib clinical trials for the treatment of neoadjuvant rectal cancer, as well as in Phase II clinical trials for other indications, such as gastric cancer and small cell lung cancer. It is also developing CRLX301, a nanopharmaceutical with docetaxel that is in preclinical stages for the treatment of solid tumors. The company was formerly known as Tempo Pharmaceuticals, Inc. and changed its name to Cerulean Pharma Inc. in October 2008. Cerulean Pharma Inc. was incorporated in 2005 and is based in Cambridge, Massachusetts.

Fundamental Ratios
Shares Outstanding27.36 M EPS-1.2 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-0.28
P/E To EPS Growth P/S P/BV1.42 Price/Cash Per Share
Price/Free Cash Flow-2.96 ROA-48.59% ROE-71.41% ROI
Current Ratio11.08 Quick Ratio Long Term Debt/Equity Debt Ratio0.13
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities13.11 M Cash From Investing Activities-30 K Cash From Operating Activities-7.94 M Gross Profit
Net Profit-8.43 M Operating Profit-7.7 M Total Assets59.38 M Total Current Assets58.58 M
Total Current Liabilities5.29 M Total Debt14.41 M Total Liabilities18.97 M Total Revenue
Technical Data
High 52 week6.56 Low 52 week0.34 Last close0.66 Last change0%
RSI49.7 Average true range1.15 Beta-2.07 Volume153.9 K
Simple moving average 20 days-32.71% Simple moving average 50 days5.05% Simple moving average 200 days-21.81%
Performance Data
Performance Week-90% Performance Month60.78% Performance Quart6.84% Performance Half-16.93%
Performance Year-76.98% Performance Year-to-date-7.37% Volatility daily74.23% Volatility weekly165.99%
Volatility monthly340.17% Volatility yearly1178.39% Relative Volume454.01% Average Volume1.75 M
New High New Low

News

2017-07-19 11:30:00 | Cerulean Pharma and Daré Bioscience Announce Closing and New Stock Symbol, _DARE_

2017-07-05 08:30:00 | Daré Bioscience Distributes Letter to Cerulean Stockholders Outlining Value Proposition and Requesting Favorable Vote at Upcoming Special Stockholder Meeting

2017-06-27 08:30:00 | Cerulean Urges Stockholders to Vote for Proposals at July 19, 2017 Special Stockholder Meeting

2017-06-19 08:30:00 | Cerulean Distributes Letter to Stockholders Requesting Favorable Vote for Proposals at July 19, 2017 Special Shareholder Meeting

2017-05-08 08:00:00 | Cerulean and Daré Announce Awards for Daré CEO

2017-03-31 16:09:30 | CERULEAN PHARMA INC. Files SEC form 10-K, Annual Report

2017-03-24 11:46:51 | CERULEAN PHARMA INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

2017-03-21 16:20:35 | CERULEAN PHARMA INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2017-03-21 15:00:12 | As Cerulean Pharma winds down, executives get a parting gift: bonuses

2017-03-20 10:15:09 | Waltham's Cerulean Pharma to cut staff, merge with San Diego biotech

2017-03-20 08:09:57 | CERULEAN PHARMA INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defini

2017-03-20 08:00:00 | Cerulean Pharma and Daré Bioscience Enter into Stock Purchase Agreement

2017-03-15 10:38:00 | Stick to Small, Fast Trades Until the Fed's out of the Way

2017-03-14 09:30:00 | Cerulean Pharma Attracts Investors and Possible Suitor, Protalix Returns to the Spotlight

2017-02-01 11:20:10 | Waltham-based cancer drug firm Cerulean Pharma may seek a buyer

2017-02-01 08:01:00 | 8:01 am Cerulean Pharma announces that its Board is conducting a comprehensive review of strategic alternatives shares halted

2017-02-01 08:00:00 | Cerulean Announces Review of Strategic Alternatives

2017-01-09 08:42:01 | 3 Reasons Why Cerulean Pharma CERU is a Great Momentum Stock

2016-12-04 16:40:00 | 5 Stocks Poised for Major Breakouts--Gold, Pharma and Tech

2016-12-02 12:51:00 | 5 Stocks Poised for Major Breakouts -- Gold, Pharma and Tech

2016-11-18 08:02:11 | CERULEAN PHARMA INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standa

2016-11-15 13:04:10 | CERULEAN PHARMA INC. Financials

2016-11-08 16:43:40 | CERULEAN PHARMA INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits

2016-11-04 05:03:45 | Cerulean reports 3Q loss

2016-11-04 01:36:59 | Edited Transcript of CERU earnings conference call or presentation 3-Nov-16 8:30pm GMT

2016-11-03 16:34:43 | Cerulean Reports Third Quarter 2016 Financial Results and Provides Corporate Update

2016-11-03 16:26:27 | CERULEAN PHARMA INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi

2016-11-03 16:11:53 | CERULEAN PHARMA INC. Files SEC form 10-Q, Quarterly Report

2016-11-03 16:11:00 | Cerulean Reports Third Quarter 2016 Financial Results and Provides Corporate Update

2016-11-03 07:07:04 | Q3 2016 Cerulean Pharma Inc Earnings Release - After Market Close

2016-10-27 07:26:09 | Cerulean to Host Third Quarter 2016 Conference Call on November 3

2016-10-27 07:00:00 | Cerulean to Host Third Quarter 2016 Conference Call on November 3

2016-10-26 07:25:04 | Cerulean Announces Promotion of Scott Eliasof, PhD to Senior Vice President and Chief Scientific Officer

2016-10-26 07:00:00 | Cerulean Announces Promotion of Scott Eliasof, PhD to Senior Vice President and Chief Scientific Officer

2016-10-19 08:18:11 | Cerulean Announces $20 Million Firm Commitment At-The-Market Stock Purchase Agreement with Aspire Capital Fund, LLC

2016-10-19 08:18:11 | Cerulean Announces Technology Platform Collaboration

2016-10-19 08:07:01 | CERULEAN PHARMA INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statemen

2016-10-19 08:01:00 | Cerulean Announces Technology Platform Collaboration

2016-10-19 08:00:00 | Cerulean Announces $20 Million Firm Commitment At-The-Market Stock Purchase Agreement with Aspire Capital Fund, LLC

2016-10-18 17:07:29 | CERULEAN PHARMA INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit

2016-10-06 07:00:00 | Cerulean Announces Data Presentations at the 2016 European Society for Medical Oncology Annual Meeting

2016-10-04 09:15:55 | Key FDA Decisions and Trial Results Expected in October

2016-09-08 08:05:52 | Key FDA Decisions and Trial Results Expected in October

2016-08-30 14:19:34 | Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial

2016-08-21 10:05:59 | 6 Companies That Destroyed Shareholders Last Week

2016-08-19 13:49:45 | Cerulean Pharma Inc CERU: What’s Next?

2016-08-18 16:21:08 | Cerulean Announces Reduction in Force

2016-08-18 11:32:00 | Cerulean Pharma CERU Stock Tumbles on Lead Kidney Cancer Drug Failure

2016-08-18 10:11:02 | Cerulean CERU Kidney Cancer Drug Disappoints in Phase II

2016-08-17 16:21:08 | Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin® Combination in Relapsed Renal Cell Carcinoma